Education
About Us
Working with TipRanks
Follow Us
Acrux Limited (AU:ACR)
ASX:ACR
ACR Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.02
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.03
Previous CloseN/A
Volume88.57K
Average Volume (3M)120.95K
Market Cap
AU$5.75M
Enterprise ValueAU$8.52M
Total Cash (Recent Filing)AU$863.00K
Total Debt (Recent Filing)AU$3.63M
Price to Earnings (P/E)―
Beta-0.28
Next Earnings
Mar 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding410,608,520
10 Day Avg. Volume76,863
30 Day Avg. Volume120,955
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)5.51
Price to Sales (P/S)4.73
P/FCF Ratio-1.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$17.85M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe significant revenue growth indicates potential market expansion and increased demand for Acrux's products, which can enhance long-term business prospects.
Gross Profit MarginAn improved gross profit margin suggests better cost management and pricing strategy, which can contribute to future profitability if maintained.
Product InnovationAcrux's focus on innovative drug delivery systems positions it well in the biopharmaceutical industry, potentially driving long-term growth through new product development.
Bears Say
High LeverageHigh leverage increases financial risk and limits flexibility, potentially impacting Acrux's ability to invest in growth opportunities or weather economic downturns.
Negative Cash FlowsPersistent negative cash flows indicate liquidity challenges, which can constrain Acrux's operational capabilities and investment in future growth.
Profitability ChallengesOngoing profitability challenges reflect operational inefficiencies and high costs, which could hinder Acrux's ability to achieve sustainable financial health.
Acrux News
ACR FAQ
What was Acrux Limited’s price range in the past 12 months?
Acrux Limited lowest share price was AU$0.01 and its highest was AU$0.03 in the past 12 months.
What is Acrux Limited’s market cap?
Acrux Limited’s market cap is AU$5.75M.
When is Acrux Limited’s upcoming earnings report date?
Acrux Limited’s upcoming earnings report date is Mar 03, 2026 which is in 13 days.
How were Acrux Limited’s earnings last quarter?
Acrux Limited released its earnings results on Aug 28, 2025. The company reported -AU$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.006.
Is Acrux Limited overvalued?
According to Wall Street analysts Acrux Limited’s price is currently Overvalued.
Does Acrux Limited pay dividends?
Acrux Limited pays a Annually dividend of AU$0.06 which represents an annual dividend yield of N/A. See more information on Acrux Limited dividends here
What is Acrux Limited’s EPS estimate?
Acrux Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acrux Limited have?
Acrux Limited has 410,608,520 shares outstanding.
What happened to Acrux Limited’s price movement after its last earnings report?
Acrux Limited reported an EPS of -AU$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Acrux Limited?
Currently, no hedge funds are holding shares in AU:ACR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acrux Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-270.27%
Trailing 12-Months
Asset Growth
-18.83%
Trailing 12-Months
Company Description
Acrux Limited
Acrux Limited (ACR) is a biopharmaceutical company based in Australia, specializing in the development and commercialization of innovative drug delivery technologies and pharmaceutical products. The company operates primarily in the healthcare sector, focusing on transdermal delivery systems, which enable medications to be absorbed through the skin. Acrux's core products include various transdermal patches and formulations designed to improve patient adherence and therapeutic outcomes in areas such as hormone replacement therapy and pain management.
Technical Analysis
Living Cell Technologies
―
Invex Therapeutics Ltd.
―
Chimeric Therapeutics Ltd.
―
Neuroscientific Biopharmaceuticals Ltd.
―
Memphasys Ltd
―
Options Prices
Currently, No data available
---